Ozempic is a powerful drug. But in addition to its weight loss benefits, people are now uncovering its potential negative effects too. While these side effects remain far from sabotaging its ever-growing popularity, there is another discovery that it might just do the same. In a study published in Nature Biology, researchers said that they have identified a gut microbe that can reduce hunger and suppress food cravings, just like semaglutide drugs do.Scientists Create GLP-1 Hormone Using Gut BacteriaA team of researchers from Jiangnan University in China demonstrated they could stimulate the secretion of glucagon-like peptide-1 (GLP-1) by increasing the population of a specific gut microbe in diabetic mice. GLP-1 is a hormone that helps regulate blood sugar levels and feelings of fullness. Its release is naturally triggered by certain foods and gut microbes, and its effects are mimicked by medications like semaglutide, the active ingredient in Ozempic.In individuals with type 2 diabetes, GLP-1 function is often impaired, causing issues with blood sugar regulation. This is why GLP-1 agonists, like Ozempic, are effective treatments. While these drugs have shown promising results, some researchers aim to discover how to stimulate the body to produce more GLP-1 naturally."The growing body of research has shown that our food cravings are driven by signals from the gut, a crucial organ in shaping dietary preferences," the authors underscored. "However, the genes, gut bacteria, and metabolites involved in regulating sugar cravings are still not fully understood."The new study suggests that gut microbes, like Bacteroides vulgatus, and their metabolites may play a role in influencing a person’s sweet cravings. In experiments, when mice were unable to produce a gut protein called Ffar4, the populations of B. vulgatus in their gut decreased. This led to a reduction in the release of a hormone called FGF21, which is associated with sugar cravings.In their experiments, when mice were treated with a metabolite from B. vulgatus, it boosted GLP-1 secretion, which in turn triggered the release of FGF21. Together, these changes led to better blood sugar control and reduced sugar cravings in the mice. While the research is still in its early stages, and its effects on humans remain to be seen, the authors believe their findings offer a promising strategy for diabetes prevention.Earlier, researchers from the University of Copenhagen claimed to have developed a revolutionary drug that decreases appetite while simultaneously increasing calorie burning—without inducing nausea, a common side effect of existing treatments. The University of Copenhagen scientists wanted to create a medication that curbs appetite and enhances calorie burning without these drawbacks. To achieve this, they focused on G protein-coupled receptors (GPCRs). The team examined more than 380 GPCRs, ranking them based on their association with haemoglobin A1C (HbA1C) levels. HbA1C is a critical biomarker for blood sugar regulation and diabetes progression, making it an essential factor in designing treatments for metabolic disorders.Their research led to the neurokinin 2 receptor (NK2R), which showed promising genetic links to both obesity and blood sugar control. NK2R has been previously studied for its roles in the gastrointestinal tract and the central nervous system. However, this research is groundbreaking in suggesting that NK2R may also influence blood sugar regulation and cardiometabolic health. Therefore, they developed a drug that targets NK2R.